RPL17 and melanoma: Study strengths include a large sample size, many treatment options reported (immunotherapy such as anti-PD-1 or combination of anti-PD-1 and anti-CTLA-4, or targeted therapies) and this is the first study investigating oncological treatments in a real-life clinical settings in advanced melanoma in several Italian centers.